4.34 USD
0 (0%)
4.34 USD
0 (0%)
Overall LUMO gets a fundamental rating of 3 out of 10. We evaluated LUMO against 525 industry peers in the Biotechnology industry. While LUMO seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, LUMO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year LUMO has reported negative net income.
- In the past year LUMO has reported a negative cash flow from operations.
- LUMO had negative earnings in each of the past 5 years.
- LUMO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -199.97%, LUMO is doing worse than 90.44% of the companies in the same industry.
- With a Return On Equity value of -710.54%, LUMO is not doing good in the industry: 81.95% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -199.97% | ||
| ROE | -710.54% | ||
| ROIC | N/A |
ROA(3y)-52.36%
ROA(5y)-41.28%
ROE(3y)-70.33%
ROE(5y)-54.18%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for LUMO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- LUMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- LUMO has less shares outstanding than it did 1 year ago.
- There is no outstanding debt for LUMO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- LUMO has an Altman-Z score of -19.20. This is a bad value and indicates that LUMO is not financially healthy and even has some risk of bankruptcy.
- LUMO has a Altman-Z score of -19.20. This is amonst the worse of the industry: LUMO underperforms 86.02% of its industry peers.
- There is no outstanding debt for LUMO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -19.2 |
ROIC/WACCN/A
WACC11.91%
2.3 Liquidity
- A Current Ratio of 2.66 indicates that LUMO has no problem at all paying its short term obligations.
- LUMO's Current ratio of 2.66 is on the low side compared to the rest of the industry. LUMO is outperformed by 69.38% of its industry peers.
- A Quick Ratio of 2.66 indicates that LUMO has no problem at all paying its short term obligations.
- LUMO has a Quick ratio of 2.66. This is in the lower half of the industry: LUMO underperforms 67.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.66 | ||
| Quick Ratio | 2.66 |
3. Growth
3.1 Past
- LUMO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.98%.
- LUMO shows a strong growth in Revenue. In the last year, the Revenue has grown by 29.71%.
- Measured over the past years, LUMO shows a very negative growth in Revenue. The Revenue has been decreasing by -30.34% on average per year.
EPS 1Y (TTM)-6.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.46%
Revenue 1Y (TTM)29.71%
Revenue growth 3Y117.26%
Revenue growth 5Y-30.34%
Sales Q2Q%10271.43%
3.2 Future
- Based on estimates for the next years, LUMO will show a very strong growth in Earnings Per Share. The EPS will grow by 40.16% on average per year.
- The Revenue is expected to grow by 53.11% on average over the next years. This is a very strong growth
EPS Next Y8.71%
EPS Next 2Y21.42%
EPS Next 3Y18.96%
EPS Next 5Y40.16%
Revenue Next Year385.58%
Revenue Next 2Y-14.99%
Revenue Next 3Y112.7%
Revenue Next 5Y53.11%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- LUMO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year LUMO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as LUMO's earnings are expected to grow with 18.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.42%
EPS Next 3Y18.96%
5. Dividend
5.1 Amount
- No dividends for LUMO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LUMOS PHARMA INC / LUMO FAQ
What is the fundamental rating for LUMO stock?
ChartMill assigns a fundamental rating of 3 / 10 to LUMO.
What is the valuation status of LUMOS PHARMA INC (LUMO) stock?
ChartMill assigns a valuation rating of 0 / 10 to LUMOS PHARMA INC (LUMO). This can be considered as Overvalued.
What is the profitability of LUMO stock?
LUMOS PHARMA INC (LUMO) has a profitability rating of 0 / 10.
What is the expected EPS growth for LUMOS PHARMA INC (LUMO) stock?
The Earnings per Share (EPS) of LUMOS PHARMA INC (LUMO) is expected to grow by 8.71% in the next year.